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Abstract The aim is to investigate the relationship of
duration of rheumatoid arthritis (RA) with safety and
effectiveness of etanercept (ETN) in Japan. Post-marketing
surveillance data for 7,099 patients treated with ETN were
analyzed. Baseline characteristics, treatment effectiveness,
incidence of adverse events (AEs), and serious AEs (SAEs)
in relation to duration of RA were studied. At baseline,
patients with RA for longer duration were older, weighed
less, had more comorbidities, allergies, and corticosteroid
use, but smoked less and had less morning stiffness. By
2–5 years with RA, more than half of the patients had
advanced to Steinbrocker radiographic stage III or IV.
Methotrexate (MTX) was the most commonly used pre-
treatment disease-modifying antirheumatic drug; however,
concomitant MTX use and its dose were lower among
patients with longer duration of RA. Remission rates
(26.6%) were greatest among patients having RA for
\2 years. Less AEs and SAEs were observed among
patients with shorter duration of RA. These results suggest
that RA treatment in Japan in the era pre-biologics may not
have been adequate to control disease activity and prevent
joint destruction. Patients with shorter duration of RA may
have better physical status which allows the opportunity to
treat more intensively putting a higher percentage of
patients in remission and possibly decreasing exposure to
SAEs.
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The evolving strategy in the United States and Europe with
regard to the control of rheumatoid arthritis (RA) disease
activity is earlier treatment with disease-modifying agents;
several guidelines support this strategy. Guidelines from
the American College of Rheumatology (ACR) state that
the ultimate goals in managing RA are to prevent or control
joint damage, prevent loss of function, and decrease pain;
initiation of disease-modifying antirheumatic drug
(DMARD) therapy within 3 months of RA diagnosis is
recommended [1]. Guidelines from the British Society of
Rheumatology state that the recognition of early RA is a
challenge and that the success of subsequent care is
dependent on this early recognition [2]. Once deﬁnite RA
has been established, British guidelines recommend that
patients be placed on disease-modifying anti-rheumatic
drug (DMARD) therapy as soon as possible; this is part of
an overall aggressive strategy that includes escalating
doses of medication, intra-articular steroid injections, par-
enteral methotrexate (MTX), and combination therapy [2].
In Europe, recommendations are even more aggressive;
guidelines from the European League Against Rheumatism
(EULAR) state that patients at risk of developing persistent
or erosive arthritis should be started with DMARDs as
early as possible, even if they have not yet ﬁlled estab-
lished classiﬁcation criteria for inﬂammatory rheumato-
logical disease [3]. Despite this, it has been reported that
between 2002 and 2005 in France, the conformity rate to
EULAR guidelines was only 54%, with just two-thirds of
early RA patients treated with DMARDs at 6 months [4].
Similarly, in the United Kingdom and Ireland between
2002 and 2007, the median time to ﬁrst DMARD treatment
was 8 months after RA symptom onset [5].
In Japan, biologic response modiﬁers are recent options
for RA disease management that may facilitate the pre-
vention of joint damage and disease progression. Four such
agents were available in Japan during the study period,
etanercept (ETN), inﬂiximab, adalimumab, and toc-
ilizumab, but concerns exist that they may not be used
early enough with a goal of achieving remission. Previous
studies have reported that ETN is safe and efﬁcacious
when compared with other therapies including MTX, inf-
liximab, adalimumab, anakinra, and other DMARDs [6–
17]. Additionally, ETN safety and effectiveness have been
conﬁrmed in a recent meta-analysis [18]. However, since
most of these studies involved relatively small numbers of
patients, an in-depth analysis of the impact of patient
proﬁles was either not possible or was generally limited in
scope. The present post-marketing surveillance (PMS)
study produced one of the largest databases available
worldwide for RA patients treated with biologics and
provided useful data about real world ETN use [19].
Results indicated that ETN is both efﬁcacious and well
tolerated as a treatment for RA patients in Japan [19]. The
study involved a large number of RA patients receiving
ETN, allowing in-depth analysis of a variety of patient
proﬁles.
The objective of this study was to investigate the rela-
tionship between the duration of RA and the safety and
effectiveness of ETN for RA in Japan. Patients from the
PMS study [19] were subclassiﬁed based on the duration of
RA and their characteristics were evaluated in relation to
effectiveness and safety of ETN. Baseline patient PMS data
also provided information about the burden of long-lasting
RA and the types of DMARDs commonly used in Japan.
Patients and methods
The PMS study protocol was reviewed and approved by the
Ministry of Health, Labor and Welfare. Patients’ eligibility
for treatment with ETN was based on the Japan College of
Rheumatology (JCR) treatment guidelines [20]. Detailed
methodology for the PMS study has been presented else-
where [19]. Brieﬂy, all RA patients who were treated with
ETN in Japan between March 2005 and 2006 were moni-
tored for 24 weeks. Registration and reporting were con-
ducted centrally, and all patients had monthly assessments
for AEs; all AEs and SAEs were recorded. Also recorded
were age, gender, complications, Steinbrocker radiographic
stage and functional class [21], duration of RA, smoking,
previous and concomitant use of corticosteroids, concom-
itant use of MTX (±the other DMARDs), and disease
activity measured by the disease activity score (DAS28/4-
ESR). A dosage between 10 and 25 mg of ETN was
administered by subcutaneous injection, two times per
week. EULAR response criteria and DAS28/4-ESR were
used to evaluate treatment effectiveness. DAS28/4-ESR
response levels were divided into 4 categories: \2.6
(remission), C2.6 and B3.2 (low disease activity),[3.2 and
B5.1 (moderate disease activity), and [5.1 (high disease
activity).
Statistical analysis
Missing data were accounted for using last-observation-
carried-forward methods, except for baseline values, which
were not carried forward. The Cochran–Armitage exact test
for trend (2-tailed) was used to determine whether there
was a trend for AEs and good response and remission over
duration of RA. Patients with RA for less than 2 years were
identiﬁed as early RA based on previous studies [17, 22].
Chi-square tests were used to assess the association
between pre-treatment of DMARD and duration of RA in
baseline characteristics. Furthermore, multiple logistic
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123regression models were applied to estimate odds ratio (OR)
and 95% conﬁdence intervals (CI) of remission and good
EULAR response in relation to duration of RA after
adjustment for major confounders (including age, sex,
baseline DAS28/4-ESR, Steinbrocker functional class IV,
duration of RA, history of infectious disease, history of
tuberculosis, presence of any comorbidities, inﬂiximab
treatment experience, and concomitant DMARD use). We
also used Cox proportional hazard models to estimate the
inﬂuence of duration of RA on serious AEs after adjust-
ment for major confounders. All statistical analyses were
performed using SAS software, version 8.2, (SAS Institute,
Inc., Cary, NC). Two-sided P values of less than .05 were
considered statistically signiﬁcant.
Results
Patient characteristics, separated by duration of RA, are
presented in Table 1. A total of 7,099 patients were treated
with ETN and completed 24 weeks of treatment. A large
majority (81%, n = 5,753) were women, and most patients
(79%, n = 5,600) were over 50 years of age. The largest
group of patients (1,593) had RA for between 5 and
10 years, while the next largest group (1,214) had RA for
between 10 and 15 years. The smallest group of patients
(707) had RA for less than 2 years. The patients with
longer duration of RA were older and had more comor-
bidities. Fig. 1 shows the relationship between duration of
RA and Steinbrocker functional class or radiographic stage.
As one may expect, the percentage of patients with
Steinbrocker class III and IV RA was higher with longer
disease duration (Fig. 1a; P\.001, Cochran–Armitage
trend test). Similarly, the percentage of patients with
Steinbrocker radiographic stage III and IV RA was higher
with longer duration (Fig. 1b; P\.001, Cochran–Armit-
age trend test).
A large number of patients received prior DMARDs
(Table 2). MTX was used by 65.8% of patients, sala-
zosulfapyridine by 25.3% of patients, and bucillamine by
Table 1 Baseline characteristics of patients participating in post-marketing surveillance of etanercept in Japan according to duration of RA
Patient characteristic Total, N (%)* Duration of RA (years) P-trend
a
Cases, N (%)*
\2 2–5 5–10 10–15 15–20 [20 Unknown
b
Gender
Men 1346 (19.0) 202 (28.6) 301 (25.5) 326 (20.5) 186 (15.3) 102 (13.4) 121 (11.1) 108 (19.5) \.001
Women 5753 (81.0) 505 (71.4) 881 (74.5) 1267 (79.5) 1028 (84.7) 657 (86.6) 969 (88.9) 446 (80.5)
Mean age (years) 58.3 54.9 56.4 57.1 58.4 58.7 62.5 60.7 \.001
Mean body weight (Kg) 53.3 55.5 54.9 54.3 52.6 52.3 50.6 51.8 \.001
Comorbidities 4132 (58.2) 361 (51.0) 654 (55.3) 886 (55.6) 730 (60.1) 482 (63.5) 714 (65.5) 306 (55.2) \.001
Past history of lung disease
c 182 (25.7) 358 (30.3) 460 (28.8) 345 (28.4) 214 (28.2) 358 (32.8) 162 (29.2) ns
Allergy 97 (13.7) 170 (14.4) 267 (16.8) 201 (16.6) 128 (16.9) 219 (20.1) 58 (10.5) \.001
Past history of smoking 1029 (14.5) 154 (21.8) 242 (20.8) 261 (16.4) 149 (12.3) 78 (10.3) 92 (8.4) 54 (9.8) \.001
Previous steroid use 6070 (85.5) 553 (78.2) 1020 (86.3) 1372 (86.1) 1042 (85.8) 675 (88.9) 951 (87.4) 459 (82.9) \.001
Mean number of years 1.0 2.5 5.3 7.5 9.8 11.0 3.5 \.001
Morning stiffness (mins) 137.7 129.6 110.9 103.9 99.3 98.9 93.2 \.001
DAS28/4-ESR (mean) 6.1 6.0 5.9 6.0 6.0 6.0 5.9 ns
Tender joints 10.1 9.8 9.7 10.0 9.7 10.0 10.3 ns
Swollen joints 9.0 8.8 8.8 9.3 9.2 9.3 9.1 .009
Patients’ VAS (mean/mm) 59.9 59.3 60.5 60.7 61.8 62.6 62.2 .001
ESR (mean/mm) 65.3 61.7 60.1 58.3 60.0 62.8 60.3 ns
CRP (mean/mm) 4.4 3.8 3.8 3.6 3.6 3.5 3.9 \.001
* Value in parentheses is percent for all, unless otherwise speciﬁed with the patient characteristic
a P-trend: The Cochran–Armitage Trend test was used for variables expressed as percentages. The Jonckheere–Terpstra test was used for other
variables
b Unknown cases were excluded from the analysis
c Infectious pneumonia or chronic obstructive lung disease
BMI body mass index, CRP C-reactive protein, DAS disease activity score, ESR erythrocyte sedimentation rate, MTX methotrexate, RA
rheumatoid arthritis, Patients’ VAS Patients’ visual analog scale
Rheumatol Int (2012) 32:1511–1519 1513
12322% of patients, while inﬂiximab was also used by 12.8%
of patients (Table 2). It was noted that some DMARDs
commonly used in United States and Europe (e.g.,
hydroxychloroquine) are not used in Japan because it is not
approved in this country. In contrast, bucillamine, mizori-
bine, tacrolimus hydrate, and lobenzarit disodium, which
are not approved in the United States or Europe, are used in
Japanese RA patients. It was also shown that concomitant
MTX use occurred more often in patients who had RA for
shorter periods of time (Fig. 2a; P\.001, Cochran–
Armitage trend test). Of patients who had RA for less than
2 years, 61.8% concomitantly used MTX while 41.8% of
patients who had RA for more than 20 years used MTX.
Figure 2b shows the relationship between MTX, dose and
duration of RA; the trend observed is a reduction in MTX
dosage with longer duration of RA (P\.001, Cochran–
Armitage trend test). For example, of patients having RA
for less than 2 years, 46.7% received MTX at a dose of
more than 8 mg weekly, while 22.1% of patients who had
RA for more than 20 years received more than 8 mg
weekly (the maximum dosage of the MTX label in Japan).
Over 80% of RA patients responded to ETN therapy,
regardless of RA duration (Fig. 3a). Effectiveness of ETN
0%
25%
50%
75%
100%
< 2 2-5 5-10 10-15 15-20 > 20
P
e
r
c
e
n
t
a
g
e
 
o
f
 
P
a
t
i
e
n
t
s
Duration of RA (years)
Class IV
Class III
Class II
Class I
0%
25%
50%
75%
100%
< 2 2-5 5-10 10-15 15-20 > 20
P
e
r
c
e
n
t
a
g
e
 
o
f
 
P
a
t
i
e
n
t
s
Duration of RA (years)
Stage IV
Stage III
Stage II
Stage I
a
1181 N= 1591 1214 759 1090 705
b 1181 N= 1591 1214 759 1090 705
Fig. 1 A comparison of duration of rheumatoid arthritis and Stein-
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Steinbrocker stage (b) in patients receiving etanercept
Table 2 Types of DMARDs previously used when switching to or
adding etanercept
Pre-treatment
DMARD class
Pre-treatment
DMARD
Number of
patients (%)
Biological DMARDs Inﬂiximab 908 (12.8)
Etanercept 108 (1.5)
Non-biological DMARDs Methotrexate 4674 (65.8)
Azathioprine 76 (1.1)
Leﬂunomide 474 (6.7)
Cyclophosphamide 38 (.5)
Mizoribine 307 (4.3)
Tacrolimus hydrate 218 (3.1)
Ciclosporin 155 (2.2)
Salazosulfapyridine 1799 (25.3)
Bucillamine 1565 (22.0)
Sodium aurothio malate 535 (7.5)
Auranoﬁn 187 (2.6)
Minocycline hydrochloride 26 (.4)
D-penicillamine 242 (3.4)
Lobenzarit disodium 22 (.3)
Actarit 316 (4.5)
By at least 20 patients
DMARD disease-modifying antirheumatic drug
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123treatment based on a response rate of ‘good’ according to
EULAR deﬁnitions was inversely related to duration of RA
(P\.001, Cochran–Armitage trend test). A signiﬁcantly
higher ‘good response’ rate was recorded for patients
having RA less than 2 years (36.1%) and between 2 and
5 years (34.2%) compared to patients having RA for more
than 20 years (21.7%) (less than 2 years multivariate
OR = 1.548, 95% CI 1.149, 2.085; P = .004; between 2
and 5 years multivariate OR = 1.517, 95% CI 1.161,
1.983; P = .002). For patients having RA for more than 5
but less than 20 years, compared to patients having RA for
more than 20 years, a trend toward a higher ‘good
response’ rate was seen which was signiﬁcant for the 15 to
20 year duration (multivariate OR = 1.432, 95% CI 1.062,
1.93; P = .019). Of patients achieving a ‘moderate
response’, the trend was opposite to that above, with the
greatest percentage of patients (62%) having RA for more
than 20 years. Although ‘good response’ is lower as the
duration of RA increases, the overall EULAR ‘good plus
moderate response’ remained constant.
In addition to achieving the greatest ‘good response’ rate,
patients having RA for duration less than 2 years also
achieve the greatest remission rate (26.2%, deﬁned as
DAS28/4-ESR \2.6; Fig. 3b). A trend toward reduced
numbers of patients achieving remission with longer dura-
tion of RA was observed (P\.001, Cochran–Armitage
trend test). Remission was achieved by 20.3% of patients
having RA for between 2 and 5 years, 16.0% of patients
having RA for between 5 and 10 years, and 10.6% of
patients having RA for more than 20 years. Compared with
patients havingRAformorethan20 years,thosehavingRA
for less than 5 years had a signiﬁcant increase in achieving
remission (less than 2 years multivariate OR = 2.163, 95%
CI 1.506, 3.107; P\.001; between 2 and 5 years multi-
variate OR = 1.593, 95% CI 1.132, 2.241; P = .008).
Among the adjustment factors, age (\65 years, OR =
1.448, 95% CI 1.164, 1.8; P = .001), gender (male, OR =
1.365, 95% CI 1.087, 1.713; P = .007), moderate or lower
disease activity (\3.2–B5.1, OR = 2.744, 95% CI 2.246,
3.352; P\.001; B2.6–B3.2, OR = 9.586, 95% CI 4.828,
19.03; P\.001), Steinbrocker functional class (I ? II,
OR = 1.878, 95% CI 1.502, 2.347; P\.001), no comor-
bidities (OR = 1.238, 95% CI 1.027, 1.494; P = .025), and
MTX use (OR = 1.264, 95% CI 1.012, 1.579; P = .039)
were associated with a signiﬁcant increase in achieving
remission using multiple logistic regression models.
Regarding safety, the rate of AEs and SAEs was lower
among patients who had RA for shorter duration (Table 3,
Cochran–Armitage p-trend\.001). For example, 31.8% of
patients who had RA for less than 2 years experienced AEs
while 37.9% of patients who had RA for more than
20 years experienced AEs. However, since other factors
can affect the incidence of SAEs, the inﬂuence of the
duration of RA on SAEs after adjustment for major con-
founders was estimated using Cox proportional hazard
models; after adjustment, results showed no signiﬁcant
association between speciﬁc duration of RA and SAEs.
Adjustment factors included age ([65 years, HR = 1.476,
95% CI 1.231,1.770; P\.001), gender (male, HR =
1.346, 95% CI 1.095, 1.656; P = .005), Steinbrocker
functional class (III ? IV, HR = 1.545, 95% CI 1.287,
1.854; P\.001), history of tuberculosis (HR = 1.413,
95% CI 1.054, 1.894; P = .021), and presence of comor-
bidities (HR = 3.020, 95% CI 2.399, 3.802; P\.001).
Likewise, the incidence of serious infections was not
affected by the duration of RA (Table 3). Interestingly, the
incidence of SAEs at any given duration was lower, in
many groups signiﬁcantly, among patients with concomi-
tant use of MTX (Table 3; lower half); using a Cox pro-
portional hazard model, MTX use signiﬁcantly decreased
risk of SAE occurrence (HR = .625, 95% CI .505, .774;
P\.001).
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123Discussion
ETN was shown to be efﬁcacious in more than 80% of the
RA patients who were not successfully treated with prior
DMARDs. Although other studies have reported that ETN
is efﬁcacious [7–13, 23–25], most of them involved rela-
tively small numbers of patients so analysis of factors that
can impact treatment outcome was either not possible or
very limited. This study is unique in that it involved a large
number of RA patients, allowing a more in-depth analysis
of a variety of factors (e.g., duration of RA, functional
class) with treatment outcome.
Maximum effectiveness has been observed in patients
who are treated concomitantly with MTX [19], which was
the DMARD most widely used concomitantly in this study.
A unique feature of the treatment of RA in Japan is the use
of domestically developed DMARDs such as bucillamine
(D-penicillamine derivative), marketed only in Japan and
Korea; it was the third most used DMARD in this inves-
tigation. The upper limit for dosing products also varies
between the United States/Europe and Japan. Patients in
this current study were treated with the locally available
DMARDs by the discretion of the attending physicians;
however, physical function deteriorated with duration of
RA. This suggests that treatment in Japan in the era pre-
biologics may not have been adequate to control RA and
that the use of newer therapies (biologics, combination
therapies) may improve outcomes. Further investigation is
recommended to evaluate the relationship between treat-
ment strategy and long-term outcome of RA patients in
Japan.
ETN was well tolerated for both early and advanced RA,
and sub-analysis showed that ETN safety and effectiveness
are maximized in patients with shorter duration of RA.
Remission rate among early RA (less than 2 years after
onset) was more than twice that of patients with 20 years of
RA. Few studies have compared effects of ETN for patients
with RA for short duration (early RA) versus longer
duration within the same study; such analysis may have
been limited by the size of the population being studied.
Because the present PMS study evaluated a very large
group of patients, dividing groups according to duration
with RA and also by level of response was possible.
Therefore, in addition to this study showing that response
to ETN treatment was evident in over 80% of patients,
signiﬁcant trends emerged showing better response in those
with RA for shorter duration than longer duration. This is
in agreement with a study evaluating patient reported
outcomes in RA patients assessed by the Health Assess-
ment Questionnaire (HAQ); ETN therapy for patients with
recent onset RA showed signiﬁcantly greater improvement
in disability measured by HAQ than for those with estab-
lished RA [26].
Because structural damage and physical function worsen
with duration of RA, these results agree with guidelines
from the United States [1] and Europe [2, 3] which suggest
early use of DMARD therapies to minimize the negative
effects of RA on patients. It is also in agreement with
results demonstrating greater clinical improvement of
moderate compared to severe RA patients treated with
ETN and/or MTX [27]. Possible reasons for the improved
response in patients with a shorter-duration RA include that
Table 3 Safety results in patients in Japan receiving etanercept according to duration of RA
Duration of RA (years) Cases, N (%) P-trend
a
\2 2–5 5–10 10–15 15–20 [20
All ETN cases
Any AEs 225 (31.8) 391 (33.1) 563 (35.3) 448 (36.9) 324 (42.7) 413 (37.9) \.001
SAEs 49 (6.9) 80 (6.8) 121 (7.6) 80 (6.6) 73 (9.6) 100 (9.2) .012
Death 7 3 7 2 4 7
Malignancy 2 3 5 2 1 2
Serious infections 21 (3.0) 43 (3.6) 63 (4.0) 41 (3.4) 27 (3.6) 50 (4.6) ns
ETN ? MTX cases
b
Any AEs 117 (26.8) 238 (33.2*) 293 (34.3) 240 (38.7) 153 (40.7) 160 (35.1) \.001
SAEs 16 (3.7*) 29 (4.1*) 45 (5.3*) 32 (5.2) 32 (8.5) 22 (4.8*) .015
Death 1 1 1 1 2 2
Malignancy 1 1 2 1 1 0
Serious infections 9 (2.1) 16 (2.2) 24 (2.8) 17 (2.7) 8 (2.1) 13 (2.9) ns
AEs adverse events, MTX methotrexate, RA rheumatoid arthritis, SAEs serious adverse events
* P\.05 compared to All ETN cases (Fisher exact test)
a P-trend: Cochran–Armitage trend test
b Patients with concomitant use of MTX (±the other DMARDs)
1516 Rheumatol Int (2012) 32:1511–1519
123pathological mechanisms may differ between early and
advanced RA; the percentage of patients taking concomi-
tant MTX was higher in RA patients having RA for shorter
duration; the dose of MTX used was higher in shorter-
duration RA patients; and longer duration of RA may cause
extra-articular complications [7, 9, 28–30], which may
narrow the choice of the treatment such as DMARDs/bi-
ologics combination therapy.
The current study demonstrated a good safety proﬁle of
ETN among Japanese RA patients in the real world.
Overall incidence of AEs, SAEs, and serious infection was
not higher compared to previous studies with ETN [7, 9,
10] or other TNF inhibitors [6, 12]. However, the use of
ETN for early RA patients may lead to even fewer adverse
reactions. Interestingly, the incidence of SAEs was much
lower among patients with concomitant MTX, and inci-
dence of serious infection did not increase among con-
comitant MTX users with long duration of RA. However,
further investigation of this point is required as patients
who can tolerate MTX may have lower risk for both SAEs
and serious infection. Cox proportional hazard models
demonstrated that some confounding factors such as older
age, advanced Steinbrocker functional class, and presence
of comorbidities could be related to the higher incidence of
SAEs among patients with longer duration of RA. In this
study, patients with shorter duration of RA were younger,
had fewer comorbidities, and had better physical function.
A variety of factors including age, comorbidities, and
concomitant DMARDs may contribute differently to the
overall safety and effectiveness outcome among patients.
However, starting aggressive treatment at an earlier time
after the diagnosis of RA may provide the most efﬁcient
treatment to patients with less risk for SAEs and greater
possibility for achieving remission, which may ultimately
improve long-term quality of life.
Limitations of this study include that this was not a
randomized controlled trial, patient proﬁles were different
between groups, there was a relatively short observational
period for a chronic disease (24 weeks), and that, following
treatment initiation with ETN, changes in functional
capacity and disease status using radiographic data were
not available. Monitoring and analysis are ongoing and it
will be interesting to compare long-term results with those
of other studies [8].
Conclusions
This sub-analysis of the PMS study data established
interesting links between duration of RA and safety/
effectiveness of ETN. We previously showed that ETN is
both effective and well tolerated by Japanese RA patients,
particularly with concomitant MTX use [19]. This analysis
shows that more than 80% of patients responded to ETN
treatment regardless of disease duration; however, a
superior safety/effectiveness proﬁle was observed among
patients with shorter duration of RA. Continued analysis of
longer-term ﬁndings will help to conﬁrm these results and
may further identify factors that affect ETN treatment
effectiveness and safety and reﬁne guidance for its use.
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